RESUMO

Thrombocytopenia with life-threatening hemorrhage in childhood immune thrombocytopenic purpura is rare, but effective therapeutic options are limited for the patient with bleeding. We report the efficacy of humanized anti-CD20 monoclonal antibody (rituximab, Rituxan) therapy for an infant with severe, refractory life-threatening immune thrombocytopenic purpura.

Assuntos

Anticorpos Monoclonais/farmacologia , Anticorpos Monoclonais/uso terapêutico , Antígenos CD20/metabolismo , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Púrpura Trombocitopênica Idiopática/tratamento farmacológico , Anticorpos Monoclonais Murinos , Humanos , Lactente , Masculino , Rituximab , Resultado do Tratamento